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Abstract
The active form of vitamin D3, 1,25(OH)2D3, has significant immunomodulatory properties and is an important determinant
in the differentiation of CD4+ effector T cells. The biological actions of 1,25(OH)2D3 are mediated by the vitamin D receptor
(VDR) and are believed to correlate with the VDR protein expression level in a given cell. The aim of this study was to
determine if and how 1,25(OH)2D3 by itself regulates VDR expression in human CD4
+ T cells. We found that activated CD4+ T
cells have the capacity to convert the inactive 25(OH)D3 to the active 1,25(OH)2D3 that subsequently up-regulates VDR
protein expression approximately 2-fold. 1,25(OH)2D3 does not increase VDR mRNA expression but increases the half-life of
the VDR protein in activated CD4+ T cells. Furthermore, 1,25(OH)2D3 induces a significant intracellular redistribution of the
VDR. We show that 1,25(OH)2D3 stabilizes the VDR by protecting it from proteasomal degradation. Finally, we demonstrate
that proteasome inhibition leads to up-regulation of VDR protein expression and increases 1,25(OH)2D3-induced gene
activation. In conclusion, our study shows that activated CD4+ T cells can produce 1,25(OH)2D3, and that 1,25(OH)2D3
induces a 2-fold up-regulation of the VDR protein expression in activated CD4+ T cells by protecting the VDR against
proteasomal degradation.
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Introduction
In addition to its fundamental activity to maintain calcium and
phosphorus homeostasis, the active form of vitamin D3, 1a,25-
dihydroxyvitamin D3 (1,25(OH)2D3), has important immunomod-
ulatory properties [1]. Epidemiological studies have shown that
vitamin D deficiency is associated with higher risk of infections
such as tuberculosis [2] and with increased risk of autoimmune
diseases such as type 1 diabetes mellitus [3] and multiple sclerosis
[4,5]. Data from animal studies support a potential protective
effect of vitamin D in autoimmune diseases [6–9], and the efficacy
of high-dose vitamin D supplementation in patients with
autoimmune diseases or infections is being tested in clinical trials
[10,11].
The biological actions of 1,25(OH)2D3 are mediated by the
vitamin D receptor (VDR) that belongs to the nuclear hormone
receptor superfamily [12,13]. Interaction of 1,25(OH)2D3 with
VDR induces heterodimerization with the retinoid X receptor
(RXR) and translocation of 1,25(OH)2D3-VDR/RXR complexes
into the nucleus [8,14–17]. The 1,25(OH)2D3-VDR/RXR
complexes bind to specific DNA sequences called vitamin D
response elements (VDRE) in target genes, and dependent on the
recruited co-regulators either augment or inhibit transcription of
the target gene [17–19].
Responses to 1,25(OH)2D3 correlate with the VDR protein
expression level in a given cell [20–22]. VDR expression varies
with cell type and cellular differentiation, and is modulated by
numerous stimuli including steroid and protein hormones,
retinoids and growth factors such as epidermal growth factor,
insulin and insulin-like growth factor [9,23]. Furthermore, in some
cell types VDR expression is modulated by the presence of its own
ligand 1,25(OH)2D3. This type of receptor regulation has in some
previous studies been called homologous regulation or auto-
regulation. The typical response to 1,25(OH)2D3 is up-regulation
of VDR expression. This can be caused by increased VDR gene
transcription, concordant with the presence of VDRE in the VDR
gene [24–29] and/or by stabilization of the VDR [22,26,30–35].
Naı¨ve CD4+ T cells have the potential to differentiate into
different types of effector cells that determine the nature of the
immune response [36,37]. One important determinant in the
differentiation of CD4+ effector T cells is vitamin D. Thus,
1,25(OH)2D3 inhibits production of IFN-c and augment the
production of IL-4, thereby restraining Th1 differentiation and
promoting Th2 differentiation, and furthermore, 1,25(OH)2D3
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inhibits Th17 differentiation and induces differentiation of Treg
[38–46]. Whether 1,25(OH)2D3 mediates its effect directly on
CD4+ T cells or indirectly via APC or maybe by a combination of
the two is still debated. If 1,25(OH)2D3 should have a direct effect
of CD4+ T cells they must express the VDR. However,
contradictory results have been reported concerning the expres-
sion of the VDR in human T cells. Most studies find that
unstimulated T cells do not express the VDR, but that they start to
express the VDR following activation with either lectins,
antibodies against the T cell receptor (TCR), or phorbol esters
in combination with ionomycin [47–56]. In contrast, some studies
find that unstimulated T cells do express the VDR [57,58]. These
opposing results might be explained by the different subpopula-
tions of leucocytes studied and the different methods for detection
of the VDR applied. Only few studies have analyzed VDR
expression in purified human CD4+ T cells and even here
contradictory results have been reported. Thus, some studies find
that unstimulated CD4+ T cells do not express the VDR but starts
to express it following activation [49,54], whereas other studies
report that unstimulated CD4+ T cells do express the VDR [57].
Two studies have indicated that activation-induced VDR
expression is augmented by 1,25(OH)2D3 in PBMC and T cells,
respectively [52,55]. In contrast, another study on purified CD4+
T cells found that unstimulated CD4+ T cells already express the
VDR, and that neither activation nor 1,25(OH)2D3 induced up-
regulation of the VDR, but that the combination did [57]. Thus,
whether and how 1,25(OH)2D3 regulates VDR protein expression
in CD4+ T cells remains to be determined.
As the VDR protein expression level is key for the cellular
sensitivity to 1,25(OH)2D3, and 1,25(OH)2D3 influences the
differentiation of CD4+ effector T cells, the aim of this study
was to determine whether 1,25(OH)2D3 regulates VDR protein
expression in human CD4+ T cells, and, if so, to elucidate the
mechanisms behind this type of VDR regulation.
Materials and Methods
Chemicals and antibodies
25(OH)D3 (BML-DM-100-0001) and 1,25(OH)2D3 (BML-
DM200-0050) were from Enzo Life Sciences, Inc., Ann Arbor,
MI. Stock solutions of 2.5 mM 25(OH)D3 and 2.4 mM
1,25(OH)2D3 were prepared in anhydrous ($99.5%) ethanol
and stored at 280uC. To determine 1,25(OH)2D3 in the
supernatants we used the 1,25-Dihydroxy Vitamin D EIA kit
(AC-62F1) from IDS, Tyne and Wear, UK according to the
manufacturer’s instructions. Antibodies used included anti-VDR
(D-6) and anti-CD3f (6B10.2) from Santa Cruz Biotechnology,
Santa Cruz, CA, anti-p53 (9282) from Cell Signaling Technology,
Danvers, MA, anti-GAPDH from (ab9485) from Abcam, Cam-
bridge, MA and HRP-rabbit anti-mouse Ig (P0260) from DAKO,
Glostrup, Denmark. Cycloheximide ready made solution 100 mg/
ml in DMSO (C4859), phorbol 12-myristate 13-acetate (PMA,
P8139), ionomycin (I0634), monensin (M5273), leptomycin B
(LMB) (L2913) and ketoconazole (K1003) were from Sigma-
Aldrich, St. Louis, MO. A fresh solution of ketoconazole 20 mg/
ml in anhydrous ethanol was prepared before each experiment.
The proteasome inhibitors lactacystin (426100) and MG-132
(474788) were from Merck Millipore, Nottingham, UK.
Ethics statement, cell culture and T cell polarization
Mononuclear cells from blood were isolated by Lymphoprep
(Axis-Shield, Oslo, Norway) density gradient centrifugation from
healthy donors after obtaining informed, written consent in
accordance with the Declarations of Helsinki principles for
research involving human objects. The study was approved by
The Committees of Biomedical Research Ethics for the Capital
Region in Denmark (H-3-2009-132). Naı¨ve CD4+ T cells were
isolated using EasySep Human Naive CD4+ T cell Enrichment Kit
(19155, Stemcell Technologies, Grenoble, France). The resulting
cell population contained 95–98% CD4+ T cells of which more
than 96% were CD45RA+. The purified naı¨ve CD4+ T cells were
cultured in serum-free X-VIVO 15 medium (1041, Lonza,
Verviers, Belgium) at 37uC, 5% CO2 at a cell concentration of
16106 cells/ml in flat-bottomed 24-well tissue culture plates
(142475) from Nunc, and stimulated with Dynabeads Human T-
Activator CD3/CD28 beads (111.31D, Life Technologies, Grand
Island, NY) at a cell to bead ratio of 5:1 for 3 days. Cells present in
the culture after 3 days were defined as activated T cells. In some
experiments 25(OH)D3 or 1,25(OH)2D3 was added to the medium
during the stimulation period. In polarization studies purified
naı¨ve CD4+ T cells were cultured and stimulated as described
above in the presence of recombinant human IL-12 (5 ng/ml,
219-IL, R&D Systems) plus human IL-4 antibody (1 mg/ml,
MAB204, R&D Systems) for Th1 polarization; in the presence of
recombinant human IL-4 (10 ng/ml, 200–04, Peprotech) plus
human IFN-c antibody (1 mg/ml, MAB285, R&D Systems) for
Th2 polarization and in recombinant human IL-1b (10 ng/ml,
201-LB, R&D Systems), recombinant human IL-6 (20 ng/ml,
206-IL, R&D Systems), recombinant human IL-23 (10 ng/ml,
1290-IL, R&D Systems) and recombinant human TGF-b1 (5 ng/
ml, 240-B, R&D Systems) plus human IFN-c antibody (1 mg/ml)
and human IL-4 antibody (1 mg/ml) for Th17 polarization.
Flow cytometry
After three days of stimulation the CD3/CD28 beads were
removed from the cells, and the cells were re-stimulated with PMA
(50 ng/ml) and ionomycin (500 ng/ml) in the presence of
monensin (3 mM) as previously described [59]. The cells were
then stained with PerCP/Cy5.5 anti-human CD4 (317428,
BioLegend), fixed and permeabilized with BD Cytofix/Cytoperm
followed by BD Perm/Wash according to the manufacturer
instructions, and finally stained intracellularly with FITC mouse
anti-human IFN-c (554551, BD Pharmingen), anti-human IL-17A
APC (17–7179, eBioscience), FITC Rat Anti-Human IL-4
(554484, BD Pharmingen) or PE anti-human IL-13 (501903,
BioLegend). Data were acquired on a FACSCalibur (BD,
Brøndby, Denmark) with CellQuest Pro software, and subse-
quently analyzed using FlowJo software.
Western blot and regression analyses
For Western blot analysis, whole cell lysates were obtained by
treatment of the cells with lysis buffer (50 mM Tris pH 7.5,
150 mM NaCl, 1 mM MgCl2) supplemented with 1% Triton X-
100, 16 Protease inhibitor cocktail (P8340, Sigma-Aldrich) and
5 mM EDTA. The samples were run under reducing conditions
on 10% polyacrylamide gels for 2 hours at 100 volt in 16
NuPAGE MOPS SDS Running buffer (XCell SureLock Mini-Cell
Module, Life Technologies). For specific detection of proteins in
the cytoplasmic and the nuclear fractions the NE-PER nuclear and
cytoplasmic extraction reagents were used according to the
manufacturer (78833, Thermo Fisher Scientific Inc., IL). An
equal number of cells per lane were used for Western blot analysis
regardless whether naı¨ve or activated T cells were studied. The
proteins were transferred to nitrocellulose membrane sheets
(Amersham Bioscience) in 16 NuPAGE Transfer buffer supple-
mented with 10% methanol for 60 min at 40 volt (XCell II Blot
Module, Life Technologies). The membranes were subsequently
blocked for 60 min in Tris-buffered saline supplemented with 5%
VDR Expression in Human T Cells
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milk powder (Blotting Grade Blocker Non Fat Dry Milk, Bio-Rad)
and 0.1% Tween 20 (P1379, Sigma-Aldrich) and incubated at 4uC
for 24 hours with primary antibodies diluted in Tris-buffered
saline supplemented with 5% bovine serum albumin (A4503,
Sigma-Aldrich) and 0.1% Tween 20. The membranes were
washed, and the proteins visualized following 60 min incubation at
room temperature with secondary HRP-rabbit anti-mouse Ig
using ECL (Amersham Biosciences) technology. The anti-VDR
antibody recognized the VDR with an approximate m.w. of
50 kDa [54], anti-p53 recognized p53 with an approximate m.w.
of 53 kDa, anti-GAPDH recognized GAPDH with an approxi-
mate m.w. of 40 kDa, and anti-CD3f recognized CD3f with an
approximately m.w. of 16 kDa under reducing conditions [60].
For band density quantification ECL exposed sheets were
analyzed in a ChemiDoc MP Imaging System from Bio-Rad.
To determine the half-life, tK, of the VDR, cells activated in the
absence or presence of 25(OH)D3 for 3 days were subsequently
treated with the protein synthesis inhibitor cycloheximide for 0–
4 hours, and the VDR protein expression levels determined by
Western blot. The density of the bands were quantified and
normalized to the density of the band of 25(OH)D3-treated cells at
time zero. Exponential regression analysis on the mean relative
band density from 3 independent experiments were performed by
use of Microsoft Excel and defined as D(t) = D(0) x e2lt, where
D(t) is the density at time t, D(0) is the initial density, i.e. the
density at time t = 0, and l is the decay constant. The half-life was
determined as tK = ln(2)/l and the mean VDR lifetime as 1/l.
To determine the increase in VDR protein expression following
treatment of the cells with proteasome inhibitors, the bands were
quantified and normalized to the density of the bands at time zero.
Linear regression analysis on the mean relative band density from
3 independent experiments were performed by use of Microsoft
Excel and defined as D(t) = at + D(0), where D(t) is the density at
time t, D(0) is the initial density, i.e. the density at time t = 0, and a
is the coefficient of inclination.
Real-time RT-PCR
mRNA for VDR and CYP24A1 were measured by real-time
RT-PCR. For this, 2–56106 CD4+ T cells were lysed in
TriReagent (Molecular Research Center) and 1-bromo-3-chlor-
opropane (BCP) added to separate the sample into an aqueous and
an organic phase. The RNA was precipitated from the aqueous
phase using isopropanol, washed with ethanol and dissolved in
RNase free water. Synthesis of complementary DNA (cDNA) was
performed using 500 ng total RNA and Omniscript reverse
transcriptase (Qiagen) in a total of 20 ml. cDNA was diluted 1:10
in TE/salmon DNA buffer (10 mM Tris pH 8.0, 1 mM EDTA,
1 mg/ml Salmon testes DNA, D7656, Sigma-Aldrich), and 5 ml
diluted cDNA (12.5 ng RNA) subsequently amplified (25 ml) in
Quantitect SYBR Green Master Mix (Qiagen) with specific
primers (100 nM) on a Stratagene MX3005P real-time PCR
machine (Agilent Technologies). The thermal profile was set to
95uC for 10 min, followed by 50 cycles of amplification: 95uC for
15 s, 58uC for 30 s, 63uC for 90 s. Signal intensity was measured at
the 63uC step and the threshold cycle (Ct) values were related to a
standard curve made with known concentrations of DNA oligos
(Ultramer oligos, Integrated DNA technologies, Leuven, Belgium)
diluted in TE/salmon DNA buffer. After amplification reactions
ran at 95uC for 60 s, 55uC for 30 s and heating slowly to 95uC to
confirm specificity of the PCR products by melting curve analysis.
Primers used for RT-PCR (sense/antisense primer) were:
VDR (CAGGCCCAACTCCAGACACACT/ATCCA-
GATTGGAGAAGCTGGACGA),
CYP24A1 (CCACGGGCAGAAGATTTGAGG/TTGTCAA-
GAGTCCGAGTTGTAAATGGT).
The data were normalized to number of cells by calculation
from the total RNA yield per cell in each sample (the raw data
represents number of target cDNA molecules measured per
12.5 ng total RNA).
Statistical analysis
Statistical analyses were performed using Student’s t test with a
5% significance level, paired observations and equal variance.
Results
Activated human CD4+ T cells produce 1,25(OH)2D3 and
up-regulates VDR protein expression in the presence of
25(OH)D3
25-hydroxyvitamin D3 (25(OH)D3) is the inactive precursor of
the active form of vitamin D3, 1,25(OH)2D3, and is considered the
most reliant parameter when determining the vitamin D status of a
subject. The normal range for serum concentrations of 25(OH)D3
is 25–170 nM, whereas the range for serum concentrations of
1,25(OH)2D3 is 60–110 pM, approximately 1000-fold lower than
25(OH)D3 [61]. It has been reported that T cells, especially
following activation, express the 25(OH)D3 1a-hydroxylase
CYP27B1 that converts the inactive 25(OH)D3 to the active
1,25(OH)2D3; however, whether T cells can convert 25(OH)D3 to
1,25(OH)2D3 in physiological relevant concentrations is a matter
of debate [55,62]. To study whether 25(OH)D3 in physiological
concentrations affects VDR expression, we first analyzed whether
T cells actually had the ability to produce 1,25(OH)2D3 from
25(OH)D3 in our experimental setup. We purified naı¨ve CD4
+ T
cells and either left them unstimulated or stimulated them with
CD3/CD28 beads in the presence of increasing concentrations of
25(OH)D3. After 3 days we measured the concentration of
1,25(OH)2D3 in the supernatants. Activated T cells clearly had the
ability to convert 25(OH)D3 to 1,25(OH)2D3 and produced
significant amounts of 1,25(OH)2D3 compared to unstimulated T
cells (Fig. 1A). In cell free control samples with 25(OH)D3 but
without T cells, 1,25(OH)2D3 could not be detected (Fig. 1A).
These results demonstrate that activated human CD4+ T cells
have the capacity to produce 1,25(OH)2D3 from 25(OH)D3. To
study how 1,25(OH)2D3 affects VDR expression levels, we
determined VDR protein expression by Western blot analysis of
T cells activated in the presence of increasing concentrations of
25(OH)D3. We found that T cell activation clearly induced VDR
protein expression even in the absence of added 25(OH)D3
(Fig. 1B). Interestingly, 25(OH)D3 significantly increased the
expression of the VDR in parallel with the 1,25(OH)2D3
production (Fig. 1A–C). Compared to T cells activated in the
absence of 25(OH)D3, VDR protein expression was increased 2.0–
2.3 fold in T cells activated in the presence of physiological
concentrations of 25(OH)D3 at 33 – 100 nM (Fig. 1C). Naive T
cells did not express the VDR, not even in the presence of
25(OH)D3 (Fig. 1B and data not shown).
These data demonstrated that T cell activation leads to VDR
expression, and that presence of the VDR ligand further up-
regulates VDR protein expression in activated T cells. To
determine whether the 25(OH)D3-induced VDR up-regulation
was caused by increased VDR gene transcription, we measured
VDR mRNA expression by real-time RT-PCR in naı¨ve T cells
and in T cells activated in the absence or presence of 25(OH)D3.
In accordance with the results obtained by the Western blot
analyses, we found that naı¨ve T cells express no or very low levels
VDR Expression in Human T Cells
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of mRNA for VDR, and that T cell activation strongly induced
VDR gene transcription (Fig. 1D). However, addition of
25(OH)D3 did not significantly increase VDR mRNA expression
in activated T cells (Fig. 1D). As control, we determined whether
addition of 25(OH)D3 had any effect on classical 1,25(OH)2D3-
responsive genes by measuring CYP24A1 mRNA in parallel with
VDR mRNA. In contrast to the VDR mRNA, addition of
25(OH)D3 during T cell activation resulted in a massive up-
regulation of CYP24A1 mRNA (Fig. 1D & E). From these
experiments we could conclude that whereas 1,25(OH)2D3-
Figure 1. Activated human CD4+ T cells produce 1,25(OH)2D3 and up-regulates VDR expression in the presence of 25(OH)D3. (A)
1,25(OH)2D3 in the supernatants of activated and unstimulated T cells and in cell free cultures incubated with the indicated concentrations of
25(OH)D3. Mean6 SEM (n= 5). (B) Representative Western blot of VDR and CD3f (loading control) expression in naı¨ve and activated T cells incubated
in the presence of the indicated concentrations (nM) of 25(OH)D3. (C) Relative VDR protein expression as determined by the density of the VDR bands
from Western blots of naı¨ve and activated T cells incubated in the presence of the indicated concentrations (nM) of 25(OH)D3. The density of the VDR
bands were normalized to the density of the VDR bands of T cells activated in the absence of 25(OH)D3. Mean + SEM (n= 7; * p,0.05). (D) Relative
VDR mRNA expression in naı¨ve and activated T cells incubated in the presence of the indicated concentrations (nM) of 25(OH)D3. The VDR mRNA
levels were normalized to VDR mRNA levels of T cells activated in the absence of 25(OH)D3. Mean + SEM (n= 4; * p,0.001). (E) Relative CYP24A1
mRNA expression in naı¨ve and activated T cells incubated in the presence of the indicated concentrations (nM) of 25(OH)D3. The CYP24A1 mRNA
levels were normalized to CYP24A1 mRNA levels of T cells activated in the absence of 25(OH)D3. Mean + SEM (n= 3; * p,0.05). (F) Representative
Western blot of VDR and CD3f (loading control) expression in T cells activated for 3 days in the presence of polarizing cytokines and anti-cytokine
antibodies as indicated. (G) Relative VDR protein expression as determined by the density of the VDR bands from Western blots of T cells treated as
described in F. The density of the VDR bands were normalized to the density of the VDR bands of T cells activated in the absence of polarizing
cytokines and anti-cytokine antibodies (Th0). Mean + SEM (n= 2).
doi:10.1371/journal.pone.0096695.g001
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responsive genes is strongly up-regulated in CD4+ T cells activated
in the presence of 25(OH)D3, VDR gene transcription is not
affected by the presence of 25(OH)D3 in CD4
+ T cells.
Finally, to study whether polarization of activated CD4+ T cells
towards the Th1, Th2 or Th17 lineage affected VDR expression
we activated naı¨ve CD4+ T cells with CD3/CD28 beads in the
presence of IL-12 plus anti-IL-4 for Th1 polarization, IL-4 plus
anti-IFN-c for Th2 polarization and IL-1b, IL-6, IL-23 and TGF-
b1 plus anti-IFN-c and anti-IL-4 for Th17 polarization. As
control, naı¨ve T cells were activated in the absence of cytokines or
anti-cytokines antibodies. In this experiment these control cells
were termed Th0 cells. After 3 days of activation we determined
VDR protein expression by Western blot analysis. We found that
activated CD4+ T cells expressed the VDR at comparable levels
independently of the polarization conditions. FACS analyses
demonstrated that the cells were not fully polarized at this early
time point, although cells polarized towards Th1 expressed more
IFN-c than cells polarized towards Th0, Th2 and Th17. Likewise
cells polarized towards Th2 expressed less IFN-c than cells
polarized towards Th0 and Th1 (Figure S1). We could not detect
IL-4 and IL-17 production at this time point.
Taken together, these experiments demonstrated that naı¨ve
CD4+ T cells neither express the VDR nor have the capacity to
produce 1,25(OH)2D3 from 25(OH)D3. Shortly after activation
with CD3/CD28 beads, they aquire the ability to produce
1,25(OH)2D3 from 25(OH)D3 and furthermore express the VDR
independently of their polarization towards the Th0, Th1, Th2 or
Th17 lineage.
Ketoconazole inhibits 1,25(OH)2D3 production and
25(OH)D3-induced up-regulation of the VDR
Although activated T cells in the presence of 25(OH)D3 clearly
produced 1,25(OH)2D3, we could not exclude the possibility that
the observed up-regulation of VDR was caused directly by
25(OH)D3 and not by 1,25(OH)2D3. To exclude this possibility,
we examined the effect of the CYB27B1 antagonist ketoconazole
[63] on 1,25(OH)2D3 production and up-regulation of the VDR.
We activated T cells in the presence of 100 nM 25(OH)D3 and
increasing concentrations of ketoconazole. After 3 days of
incubation we measured the concentration of 1,25(OH)2D3 in
the supernatants and the intracellular VDR protein expression
levels. We found that ketoconazole efficiently inhibited the
conversion of 25(OH)D3 to 1,25(OH)2D3 (Fig. 2A) and in parallel
inhibited VDR up-regulation (Fig. 2B & C). These results
indicated that ketoconazole inhibited 1,25(OH)2D3 production
and thereby 1,25(OH)2D3-induced VDR up-regulation. If this was
the case and ketoconazole did not inhibit VDR gene transcription,
then addition of 1,25(OH)2D3 should rescue up-regulation of the
VDR protein. Consequently, we activated T cells in the presence
of 10 nM 1,25(OH)2D3 and increasing concentrations of ketoco-
nazole. We found that in contrast to 25(OH)D3, exogenous
1,25(OH)2D3 induced up-regulation of the VDR protein in the
presence of ketoconazole (Fig. 2B & C). These experiments
indicated that it is 1,25(OH)2D3 and not 25(OH)D3 that increases
VDR protein expression in activated T cells.
1,25(OH)2D3 increases the half-life of the VDR
The above data indicated that 1,25(OH)2D3 mainly mediates
VDR up-regulation by stabilization of the VDR. To directly
determine how 1,25(OH)2D3 affects the half-life of the VDR, we
activated T cells in the absence or presence of 100 nM 25(OH)D3
for 3 days. Subsequently, we treated the cells with the protein
synthesis inhibitor cycloheximide for 0–4 hours and determined
the VDR protein expression levels by Western blot analysis of
whole cell lysates. We found that cycloheximide caused a gradual
decrease in VDR protein expression with time in both untreated
cells and cells treated with 25(OH)D3 (Fig. 3A). Regression
analyses of the relative mean values of the density of the VDR
bands gave the equations D(t) = 0.37e20.41t with R2 = 0.88 and
D(t) = 0.89e20.24t with R2 = 0.90 for T cells activated in the
absence and presence of 25(OH)D3, respectively (Fig. 3B). From
these results, the half-life (tK) of the VDR was calculated to 1.7 h
in untreated cells and 2.9 h in cells treated with 25(OH)D3
resulting in a mean VDR lifetime of 2.5 h and 4.2 h, respectively.
Thus, we could conclude that 1,25(OH)2D3 up-regulates the VDR
by increasing tK and the mean lifetime of the VDR by
approximately 1.7-fold.
Figure 2. Ketoconazole inhibits 1,25(OH)2D3 production and
up-regulation of the VDR. (A) 1,25(OH)2D3 in the supernatants of T
cells activated in the presence of 100 nM of 25(OH)D3 and the indicated
concentrations of ketoconazole. Mean + SEM (n= 3; * p,0.05). (B)
Representative Western blot of VDR and CD3f (loading control)
expression in T cells activated in the presence of the indicated
concentrations of ketoconazole, 25(OH)D3 (100 nM) and 1,25(OH)2D3
(10 nM). (C) Relative VDR protein expression in T cells activated in the
presence of the indicated concentrations of ketoconazole, 25(OH)D3
(100 nM) and 1,25(OH)2D3 (10 nM). The density of the VDR bands
obtained by Western blot analysis were normalized to the density of the
VDR bands of T cells stimulated in the absence of ketoconazole,
25(OH)D3 and 1,25(OH)2D3. Mean + SEM (n= 3; * p,0.01).
doi:10.1371/journal.pone.0096695.g002
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Previous studies in other cell types than T cells have indicated
that the VDR rapidly shuttles between the cytosol and the nucleus.
The VDR is thus distributed to both the cytosol and the nucleus in
the absence of 1,25(OH)2D3, and interaction of 1,25(OH)2D3 with
the VDR shifts the localization of the VDR in favor of the nucleus
in most but not all cell types studied [8,15–17]. To study the
intracellular distribution of the VDR in T cells, we activated the
cells in the absence or presence of 100 nM 25(OH)D3 for 3 days
Figure 3. 1,25(OH)2D3 increases the half-life of the VDR. (A) Representative Western blot of VDR and CD3f (loading control) in whole cell
lysates from T cells activated in the absence or presence of 25(OH)D3 (100 nM) and then treated with cycloheximide (10 mg/ml) for the time indicated.
The half-lives (tK) for the VDR in the absence or presence of 25(OH)D3 are given below the blot. (B) Relative VDR protein expression obtained from
Western blot analysis of whole cell lysates from T cells activated in the absence (W) or presence (W +25(OH)D3) of 25(OH)D3 (100 nM) and then
treated with cycloheximide (10 mg/ml) for the time indicated. The density of the VDR bands were normalized to the density of the VDR bands at time
zero of T cells stimulated in the presence of 25(OH)D3. Shown are the mean relative densities from 3 independent experiments and the curves
obtained by regression analysis for W (D(t) = 0.37e20.41t, R2 = 0.88) and W +25(OH)D3 (D(t) = 0.89e20.24t, R2 = 0.90). (C) Representative Western blot of
VDR, GAPDH and CD3f (loading controls) expression in the cytoplasmic (C) and nuclear (N) fractions of T cells activated in the absence or presence of
25(OH)D3 (100 nM) and T cells activated in the absence of 25(OH)D3 and then treated for 4 h with 1,25(OH)2D3 (10 nM). (D) Distribution of the VDR in
the cytoplasmic (C) and nuclear (N) fractions of T cells treated as described in (C), mean + SEM (n$4; * p,0.01). (E) Representative Western blot of
VDR and CD3f (loading control) expression in the cytoplasmic fraction of T cells treated as described in (A). (F) Relative VDR protein expression
obtained from Western blot analysis of the cytoplasmic fraction from T cells activated in the absence (C) or presence (C +25(OH)D3) of 25(OH)D3
(100 nM) and then treated with cycloheximide (10 mg/ml) for the time indicated. The density of the VDR bands were normalized to the density of the
VDR bands at time zero of T cells stimulated in the presence of 25(OH)D3. Shown are the mean relative densities from 3 independent experiments
and the curves obtained by regression analysis for C (D(t) = 2.11e20.44t, R2 = 0.94) and C +25(OH)D3 (D(t) = 0.76e20.26t, R2 = 0.70). (G) Representative
Western blot of VDR expression in the nuclear fraction of T cells treated as described in (A). (H) Relative VDR protein expression obtained from
Western blot analysis of the nuclear fraction from T cells activated in the absence (N) or presence (N +25(OH)D3) of 25(OH)D3 (100 nM) and then
treated with cycloheximide (10 mg/ml) for the time indicated. The density of the VDR bands were normalized to the density of the VDR bands at time
zero of T cells stimulated in the presence of 25(OH)D3. Shown are the mean relative densities from 3 independent experiments and the curves
obtained by regression analysis for N (D(t) = 0.68e20.53t, R2 = 0.99) and N +25(OH)D3 (D(t) = 0.86e20.23t, R2 = 0.90).
doi:10.1371/journal.pone.0096695.g003
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and subsequently determined the VDR protein expression levels in
the cytoplasmic and nuclear fractions by Western blot analysis
(Fig. 3C). We found that in the absence of 25(OH)D3 the VDR
was distributed with approximately 35% in the cytoplasma and
65% in the nucleus, and that the presence of 25(OH)D3 induced a
significant redistribution of the VDR resulting in localization of
approximately 15% of the VDR in the cytoplasma and 85% in the
nucleus (Fig. 3D). To investigate whether it actually was the active
1,25(OH)2D3 that caused the VDR distribution, we treated T cells
that had been activated in the absence of 25(OH)D3 with 10 nM
1,25(OH)2D3 for the last 4 hours of the stimulation period and
subsequently determined the VDR protein expression levels in the
cytoplasmic and nuclear fractions. We found that approximately
95% of the VDR was located in the nucleus in T cells treated with
1,25(OH)2D3 (Fig. 3C and D), and we could conclude that
1,25(OH)2D3 induces a substantial redistribution of the VDR in
activated T cells.
To study whether the 1,25(OH)2D3-induced redistribution of
the VDR to the nucleus could explain the increased tK of the
VDR, we activated T cells in the absence or presence of 100 nM
25(OH)D3. Subsequently we treated them with cycloheximide for
0–4 hours and determined the VDR protein expression levels in
the cytoplasmic and nuclear fractions separately by Western blot
analysis. We found that the half-lives of the VDR were quite
similar in the cytoplasma and nucleus, and that 1,25(OH)2D3
augmented the tK of VDR to the same degree in both
compartments (Fig. 3E–H). Thus, 1,25(OH)2D3 increased the
tK from 1.6 to 2.7 h in the cytosol and from 1.3 to 3.0 h in the
nucleus.
1,25(OH)2D3 stabilizes the VDR by protecting it from
proteasomal degradation
To this point, our data indicated that the degradation rate of the
VDR in human CD4+ T cells is regulated by 1,25(OH)2D3.
Degradation of most cytosolic and nuclear proteins is carried out
by the ubiquitin-proteasome pathway [64,65]. To determine
whether the VDR is degraded by the proteasomes in T cells, we
activated the cells in absence of 25(OH)D3 for 3 days.
Subsequently, we treated the cells with 0 to 10 mM of the
proteasome inhibitor lactacystin for 1 hour, and then added
cycloheximide for 1 additional hour. Finally, we determined the
VDR protein expression levels by Western blot analysis of the
whole cell lysates and the cytosolic and nuclear fractions (Fig. 4A &
B). Cells treated with cycloheximide but without lactacystin
expressed approximately 50% of the VDR compared to untreated
cells in both whole cell lysates and the cytosolic and nuclear
fractions (Fig. 4A–C) in agreement with a high VDR degradation
rate in the absence of 1,25(OH)2D3. Increasing concentrations of
lactacystin gradually rescued VDR protein expression, and
inhibition of the proteasome with 10 mM lactacystin completely
blocked VDR degradation (Fig. 4A–C). From these data we could
conclude that in the absence of 1,25(OH)2D3 the VDR is
spontaneously degraded by the proteasome.
The above data suggested that 1,25(OH)2D3 induces VDR up-
regulation by protecting the VDR against spontaneous degrada-
tion in the proteasome. If 1,25(OH)2D3 inhibits the proteasomal
degradation of the VDR, it should be expected that the relative
VDR protein expression levels increase more rapidly in the
absence than in the presence of 1,25(OH)2D3 when proteasomal
degradation is inhibited. To test this hypothesis, we activated T
cells in the absence or presence of 100 nM 25(OH)D3.
Subsequently, we treated the cells with lactacystin for 0–4 hours
and determined the VDR protein expression levels (Fig. 5A). The
density of the VDR bands were quantified and normalized to the
density of the VDR bands at time 0. The relative VDR protein
expression levels increased more rapidly in cells not treated with
25(OH)D3 than in cells treated with 25(OH)D3 (Fig. 5B). Similar
results were obtained when the proteasome inhibitor MG-132 was
used instead of lactacystin (data not shown). From these
experiments we could conclude that 1,25(OH)2D3 protects the
VDR against proteasomal degradation.
To investigate whether 1,25(OH)2D3 specifically protects the
VDR against proteasomal degradation or whether 1,25(OH)2D3
inhibits proteasomal degradation in general, we simultaneously
determined the expression levels of the VDR and the tumor
suppressor protein p53, which normally is rapidly degraded by the
proteasome [66]. We activated T cells in the absence of 25(OH)D3
for 3 days and subsequently treated the cells with increasing
concentrations of 1,25(OH)2D3 for 4 hours. We then determined
the levels of VDR and p53 by Western blot analysis of the whole
cell lysates. As expected, we found that 1,25(OH)2D3 treatment
resulted in increased levels of the VDR; however, 1,25(OH)2D3
did not affect p53 levels (Fig. 5C and D). Thus, we could conclude
that 1,25(OH)2D3 specifically protects the VDR against proteaso-
mal degradation.
To determine whether up-regulation of the VDR observed in
cells treated with proteasome inhibitors had any physiological
consequences for 1,25(OH)2D3-induced gene regulation, we
activated T cells in the absence of 25(OH)D3 for 3 days.
Subsequently, we treated the cells with increasing concentrations
of 1,25(OH)2D3 for 12 hours in the absence or presence of the
proteasome inhibitor lactacystin and then determined the
CYP24A1 mRNA level. Cells treated with lactacystin were more
sensitive to 1,25(OH)2D3 treatment. Thus, lactacystin-treated cells
clearly started CYP24A1 gene transcription at lower concentra-
tions of 1,25(OH)2D3 and showed significantly enhanced
CYP24A1 transcription compared to cells not treated with
lactacystin (Fig. 5E). Taken together, these experiments demon-
strated that 1,25(OH)2D3 specifically protects the VDR against
proteasomal degradation and that the response to 1,25(OH)2D3
correlates with the level of VDR protein expression in human
CD4+ T cells.
Leptomycin B neither inhibits nuclear export nor
degradation of the VDR
From the results above it could be concluded that 1,25(OH)2D3
inhibits the proteasomal degradation of the VDR in human CD4+
T cells. At the same time 1,25(OH)2D3 induces translocation of the
VDR from the cytosol to the nucleus. Previous studies in
osteoblasts have suggested that the VDR is protected against
proteasomal degradation in the nucleus [34], and this could also
be the case for T cells. However, we found similar tK for the
VDR in the cytosol and the nucleus, and at first sight this indicated
that translocation of the VDR to the nucleus did not explain the
1,25(OH)2D3-induced protection of the VDR. Yet, other studies
have shown that the VDR rapidly shuttles between the cytosol and
the nucleus [67], and at least two different scenarios could thus be
envisioned: (i) 1,25(OH)2D3-induced protection of the VDR
against proteasomal degradation is independent of VDR localiza-
tion and takes place equally well in the cytosol and the nucleus, or
(ii) the VDR is mainly degraded in the cytosol, and 1,25(OH)2D3
protects the VDR by affecting the cytoplasmic-nuclear shuttling in
favor for localization of the VDR in the nucleus. To study which of
these models that is valid in T cells, we set out to determine how
blocking of the nuclear export of the VDR affected VDR stability.
If scenario (i) was correct then blocking nuclear export should not
affect the VDR protein expression level; however, if scenario (ii)
was correct blocking nuclear export should lead to increased VDR
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levels. Leptomycin B (LMB) inhibits CRM1/exportin1 [68] and
thereby blocks nuclear export of a variety of molecules including
p53. p53 is normally exported from the nucleus to the cytoplasma
where it is degraded, and treatment of cells with LMB
consequently results in increased levels of p53 [66]. As it has
been reported that LMB also blocks the export of unliganded
VDR from the nucleus [67], we activated T cells in the absence of
25(OH)D3 for 3 days and subsequently treated the cells with
increasing concentrations of LMB for 4 hours. We then
determined the levels of VDR and p53 by Western blot analysis
of the whole cell lysates. As expected, we found that LMB
treatment resulted in increased levels of p53; however, LMB did
not affect VDR levels (Fig. 6A and B). This suggested that scenario
(i) was correct. To verify that LMB actually did block export of
unliganded VDR from the nucleus, we determined the levels of
VDR and p53 in the cytosolic and nuclear fractions of cells
activated in the absence of 25(OH)D3 and subsequently treated
with increasing concentrations of LMB. Surprisingly, unlike p53
the VDR did not accumulate in the nucleus after LMB treatment
(Fig. 6C). From these results we could conclude that CRM1/
exportin1 is not required for nuclear export of the VDR in T cells,
and consequently we could not determine whether VDR in
primary T cells is degraded in the cytosol, the nucleus or in both
compartments.
Discussion
In this study we determined the effect of 1,25(OH)2D3 on VDR
expression in purified human CD4+ T cells activated with CD3/
CD28 beads in vitro. We confirmed that naı¨ve CD4+ T cells do not
express the VDR. Activation of the CD4+ T cells induces VDR
expression, and we found that 1,25(OH)2D3 further up-regulates
the VDR protein expression approximately 2-fold by protecting
the VDR against proteasomal degradation. Previous studies in
other cell types have demonstrated that 1,25(OH)2D3 can up-
regulate the VDR by increasing VDR mRNA expression [24–29]
and/or by stabilizing the VDR at the protein level [22,26,30–35].
Contradictory studies on VDR expression and the effect of
1,25(OH)2D3 on VDR expression in T cells have been published.
Thus, two previous studies have indicated that activation-induced
VDR expression is augmented by 1,25(OH)2D3 in PBMC and T
cells, respectively [52,55]. In contrast, another study found that
unstimulated CD4+ T cells already express the VDR, and that
neither activation nor 1,25(OH)2D3 induces up-regulation of the
VDR, but that the combination does [57]. Thus, whether and how
1,25(OH)2D3 regulates VDR expression in CD4
+ T cells has
remained unknown until the present study.
To mimic physiological conditions, we incubate the cells with
physiological concentrations of the precursor 25(OH)D3, which is
found in 1000-fold higher concentrations in serum than
1,25(OH)2D3. We found that activated T cells can indeed convert
25(OH)D3 to the active 1,25(OH)2D3. The capacity of activated T
cells to produce 1,25(OH)2D3 is in good agreement with studies
demonstrating the expression of the 1a-hydroxylase CYP27B1 in
activated T cells [55,62]. In contrast to our results, Jeffery et al.
found that human T cells did not have the capacity to produce
1,25(OH)2D3, although they found that T cell activation induced
significant up-regulation of CYP27B1 [62]. We believe that this
discrepancy can be explained by the fact that Jeffery et al.
measured 1,25(OH)2D3 production after only 24 hours of T cell
activation, whereas we measured it after 3 days of activation.
We found that 1,25(OH)2D3 up-regulates VDR protein
expression approximately 2-fold in activated T cells without
affecting VDR mRNA expression. As control we analyzed the
effect of 25(OH)D3 on known 1,25(OH)2D3-responsive genes like
CYP24A1 that became strongly up-regulated in CD4+ T cells
activated in the presence of 25(OH)D3, while VDR gene
transcription was unaffected by the presence of 25(OH)D3 in
CD4+ T cells. This is in good agreement with observations in
mouse fibroblasts and rat intestinal epithelial cells [30], the human
Figure 4. The VDR is spontaneously degraded by the proteasomes. (A, B) Representative Western blot of VDR and CD3f (loading control) in
(A) whole cell lysates and (B) cytoplasmic (C) and nuclear (N) fractions of T cells activated for 3 d in the absence of 25(OH)D3 and then pre-treated with
the indicated concentrations of lactacystin (mM) for 1 h before treatment with cycloheximide (10 mg/ml) as indicated for one additional h. (C) Relative
VDR protein expression obtained from Western blot analysis of whole cell lysates (W), cytoplasmic (C) and nuclear (N) fractions from T cells treated as
described in A and B. The density of the VDR bands were normalized to the density of the VDR bands of T cells not treated with lactacystin and
cycloheximide. Results are presented as mean + SEM (n= 3).
doi:10.1371/journal.pone.0096695.g004
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breast cancer cell line T-47D [32], the human osteoblastic
sarcoma cell line MG-63 [33], and the human keratinocyte cell
line HaCaT [22], in which 1,25(OH)2D3 up-regulated VDR
protein expression 2-3-fold without affecting VDR mRNA
expression. Our results is also concordant with a previous study
that found that 1,25(OH)2D3 up-regulated VDR expression in
PBMC following activation; however, the types of cells that up-
regulated the VDR was not identified in that study [52]. Our
results are in contrast to the study by Baeke et al. which found that
1,25(OH)2D3 up-regulated VDR mRNA expression in activated T
cells [55]. This discrepancy might be explained by the facts that
Baeke et al. in contrast to us did not study purified subpopulations
of T cells and furthermore used 1,25(OH)2D3 in concentrations
more than 100 fold higher than physiological concentrations.
Interestingly, a recent study found that 25(OH)D3 induced a 2-fold
up-regulation in VDR mRNA expression in human monocytes
[29]. Thus, the presence of monocyte in T cell preparations could
confuse the results and might explain some of the inconsistent
results on VDR regulation in T cells. Our results are also in
contrast to a study by Veldman et al. which found that
unstimulated CD4+ T cells already express the VDR, and that
neither activation or 1,25(OH)2D3 induces up-regulation of the
VDR, but that the combination does [57]. The discrepancy
between our study and the study by Veldman et al. most probably
can be explained by the different methods used to detect the VDR.
Whereas we used the highly specific and sensitive anti-VDR
antibody D-6 in Western blot analyses [69], Veldman et al. used a
catching-ELISA with the IVG8C11 anti-VDR antibody produced
against partially purified pig VDR [70] as the catching antibody.
Later studies have demonstrated that IVG8C11 has extremely low
sensitivity against the VDR [69], and thus the signals measured in
the ELISA by Veldman et al. probably did not result from VDR
binding.
By inhibiting CYP27B1 with ketoconazole we could block the
conversion of 25(OH)D3 to 1,25(OH)2D3 and the up-regulation of
the VDR protein expression in T cells activated in the presence of
25(OH)D3. In contrast, exogenous added 1,25(OH)2D3 still
induced VDR protein up-regulation in the presence of ketocona-
zole. Although ketoconazole also inhibits other members of the
cytochrome P450 superfamily, these results indicated that it is only
the active form of vitamin D3 that has the potential to up-regulate
the VDR. By blocking protein synthesis with cycloheximide we
found that 1,25(OH)2D3 increases the half-life of the VDR in T
cells by approximately 1.7-fold in accordance with previous studies
in other cell types, which found that 1,25(OH)2D3 increased the
VDR half-life approximately 2-fold [22,30,33].
We found that in the absence of 1,25(OH)2D3 the VDR
distributes with approximately 35% in the cytosol and 65% in the
nucleus in activated T cells. Addition of 1,25(OH)2D3 caused a
significant redistribution of the VDR resulting in localization of
more than 90% of the VDR in the nucleus. These findings extend
prior studies in other cell types, which indicated that the VDR
Figure 5. 1,25(OH)2D3 stabilizes the VDR by protecting it from proteasomal degradation. (A) Representative Western blot of VDR and
CD3f (loading control) expression in whole cell lysates of T cells activated for 3 d in the absence or presence of 25(OH)D3 (100 nM) and then treated
with lactacystin (10 mM) for the time indicated. The coefficients of inclination (coi) obtained from the curves in B are given below the blots. (B)
Relative VDR protein expression obtained from Western blot analysis of whole cell lysates (W) of T cells activated for 3 d in the absence or presence (+
25(OH)D3) of 25(OH)D3 (100 nM). The density of the VDR bands were normalized to the density of the VDR bands at time zero of T cells activated in
the absence or presence of 25(OH)D3, respectively. Shown are the mean relative densities from 3 independent experiments and the curves obtained
by linear regression analysis of the mean values. (C) Representative Western blot of VDR, p53 and CD3f (loading control) in whole cell lysates of T cells
activated for 3 d in the absence of 25(OH)D3 and then treated with the indicated concentrations of 1,25(OH)2D3 for 4 h. (D) Relative VDR and p53
protein expression obtained from Western blot analysis of whole cell lysates from T cells treated as described in C. The density of the VDR and p53
bands were normalized to the density of the VDR and p53 bands of T cells not treated with 1,25(OH)2D3, respectively. Results are presented as mean
+ SEM (n= 3; * p,0.05). (E) Relative CYP24A1 mRNA expression in T cells activated for 3 d in the absence of 25(OH)D3 and then treated with
increasing concentrations of 1,25(OH)2D3 for 12 hours in the absence or presence of 10 mM lactacystin. The CYP24A1 mRNA levels were normalized
to CYP24A1 mRNA levels of T cells not treated with1,25(OH)2D3. Results are presented as mean + SEM (n= 5; * p,0.05).
doi:10.1371/journal.pone.0096695.g005
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distributes evenly between the cytosol and the nucleus in the
absence of 1,25(OH)2D3, and that 1,25(OH)2D3 facilitates
translocation of the VDR to the nucleus [14–17]. It has been
suggested that nuclear import of the VDR is important for
stabilization of the VDR in osteoblasts [34]. The ubiquitin-
proteasome pathway is the major route of disposal for most
cytosolic and nuclear proteins [64,65]. In agreement, our data
demonstrated that human CD4+ T cells contain proteasome
activity that degrades the VDR. Blocking proteasome activity
increased the VDR levels to the same extent in the cytosol and
nucleus. At first sight, this indicated that the VDR is degraded with
similar kinetics in these compartments. However, the VDR most
probably rapidly shuttles between the cytosol and the nucleus, and
we could therefore not exclude that the VDR mainly is degraded
in either the cytosol or the nucleus. To determine where the VDR
is degraded, we studied the effect of LMB known to block nuclear
export of a series of molecules [66,68]. LMB has previously been
reported to block nuclear export of unliganded VDR-GFP
chimeras in transfected cell lines [67]; however, we clearly
demonstrated that LMB neither inhibits nuclear export nor affects
degradation of the VDR in CD4+ T cells. Consequently, we could
not determine the primary site for VDR degradation, but we could
conclude that 1,25(OH)2D3 inhibits the spontaneous proteasomal
degradation of the VDR and thereby increases the half-life of the
VDR in CD4+ T cells. These results are in good agreement with
previous studies in other cell types, which found that 1,25(OH)2D3
inhibits ubiquitination and thereby proteasomal degradation of the
VDR in the keratinocyte cell line HaCaT [22] and in Cos-1 cells
[34]. 1,25(OH)2D3 might inhibit the proteasomal degradation of
the VDR by inducing conformational changes of the VDR either
directly or by promoting the association between VDR and RXR.
Alternatively, 1,25(OH)2D3 might influence the expression of
molecules involved in VDR degradation such as SUG1 [71] and
CDK11B [72] and thereby affect VDR degradation. Future
studies are required to precisely elucidate the mechanisms by
which 1,25(OH)2D3 inhibits the proteasomal degradation of the
VDR. Finally, we found that in parallel with up-regulation of
VDR protein expression, proteasome inhibition leads to enhanced
1,25(OH)2D3-induced gene regulation. This is in good agreement
with previous studies that found VDR up-regulation and enhanced
sensitivity to 1,25(OH)2D3 following proteasome inhibition in
keratinocytes and osteoblasts [22,35].
Whereas most ligands desensitize their receptors, 1,25(OH)2D3
up-regulates its receptor and thereby increases the sensitivity of T
cells for 1,25(OH)2D3. Combined with our observation that the
VDR is expressed by all naı¨ve T cells independently of the
cytokine environment during the early stages of activation this
substantiates that 1,25(OH)2D3 can play important roles in the
early stages of T cell differentiation if found in sufficiently high
local concentrations [38–46,62].
In conclusion, our study establishes that naı¨ve human CD4+ T
cells do not express the VDR but that they start to express the
VDR following stimulation via the TCR and CD28 independently
of the presence of Th1, Th2 and Th17 polarizing cytokines. We
further show that activated CD4+ T cells produce biological active
concentrations of 1,25(OH)2D3 when provided with physiological
concentrations of 25(OH)D3, and that 1,25(OH)2D3 induces a 2-
fold up-regulation of VDR protein expression. We demonstrate
that the 1,25(OH)2D3-induced VDR up-regulation is not caused
by increased VDR mRNA expression but by protecting the VDR
against proteasomal degradation. Finally we show that VDR up-
regulation has functional consequences for 1,25(OH)2D3-respon-
sive genes and thereby most probably consequences for CD4+ T
cell differentiation and the ensuing immune response.
Supporting Information
Figure S1 IFN-c expression in polarized CD4+ T cells
activated for 3 days. FACS plots of naı¨ve CD4+ T cells
activated for 3 days with CD3/CD28 beads in the presence of IL-
12 plus anti-IL-4 for Th1 polarization, IL-4 plus anti-IFN-c for
Th2 polarization and IL-1b, IL-6, IL-23 and TGF-b1 plus anti-
IFN-c and anti-IL-4 for Th17 polarization. As control, naı¨ve T
cells were activated in the absence of cytokines or anti-cytokines
antibodies (Th0 cells). The cells were stained for cell surface
expression of CD4 and intracellular expression of IFN-c and
analyzed by flow cytometry.
(TIF)
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Figure 6. Leptomycin B neither inhibits nuclear export nor
degradation of the VDR. (A) Representative Western blot of VDR,
p53 and CD3f (loading control) in whole cell lysates of T cells activated
for 3 d in the absence of 25(OH)D3 and then treated with the indicated
concentrations (ng/ml) of leptomycin B (LMB) for 4 h. (B) Relative VDR
and p53 protein expression obtained from Western blot analysis of
whole cell lysates from T cells treated as described in A. The density of
the VDR and p53 bands were normalized to the density of the VDR and
p53 bands of T cells not treated with LMB, respectively. Results are
presented as mean + SEM (n= 3; * p,0.05). (C) Representative Western
blot of VDR, p53 and CD3f (loading control) in cytoplasmic (C) and
nuclear (N) fractions of T cells treated as described in A.
doi:10.1371/journal.pone.0096695.g006
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